Introduction {#S1}
============

Glioblastoma multiforme (GBM), or World Health Organization (WHO) grade IV astrocytoma, is the most common type of primary brain tumor in adults. In addition, it is the most malignant and aggressive form of glioma and among the most lethal ones because of its highly invasive potential and least effective treatment available among solid tumors.^[@R1]^ Various genetic alterations lead to the development of malignant phenotype expression in human GBM.^[@R2],[@R3]^ Heterogeneous pathological features associated with complex molecular heterogeneity are the major problems for the development of effective drug targets.^[@R4],[@R5]^

GBMs can arise either *de novo* (primary) or progress to GBM from low grade gliomas (secondary) with two distinct molecular pathways.^[@R3]^ Significant indicators of anaplasia in gliomas include: atypia (coarse nuclear chromatin, nuclear pleomorphism, multinucleation), mitotic activity, cellularity, microvascular proliferation, and necrosis. Necrosis with the microvascular or endothelial cell proliferations is a histological hallmark of glioblastoma.^[@R3]--[@R5]^

Poly (ADP-ribose) polymerase 1 (*PARP-1*) gene, located to 1q42, is 43 kb-long and divided into 23 exons (OMIM 173870). Grube and Burkle^[@R6]^ suggested that a higher *PARP-1* action capacity may contribute to an efficient maintenance of genome integrity. Yu *et al.*^[@R7]^ showed that *PARP-1* activation is required for translocation of apoptosis-inducing factor (AIF) from the mitochondria to the nucleus. PARP-1 protein is then proteolytically cleaved at the onset of apoptosis by caspase-3;^[@R8]^ furthermore, *PARP-1* activity and poly (ADP-ribose) (PAR) polymer, mediate PARP-1-induced cell death.^[@R8],[@R9]^

Genetic and pharmacological studies found that overexpression of *PARP-1* is a key mediator of programmed-necrotic cell death *in vivo*. In addition, *PARP-1* appears to be also involved in programmed cell death processes, such as apoptosis or macroautophagocytotic cell death.^[@R10]^ Microarray analysis showed that PARP-1 mRNA expression in histologically normal tissues is low and uniform across a wide variety of tissues.^[@R11]^ Furthermore, microarray analysis of *PARP-1* gene expression in more than 8000 samples revealed that *PARP-1* is more highly expressed in several types of tumors compared with the equivalent normal tissue. Overall, the most striking differences in *PARP-1* gene expression have been observed in breast, ovarian, endometrial, lung, skin cancers, and non-Hodgkin\'s lymphoma.^[@R11]^

The present study was undertaken to evaluate the expression of PARP-1 protein in normal brain tissues and primary glioblastomas (grade IV WHO) with immunohistochemistry.

Materials and Methods {#S2}
=====================

Patient and control brain samples
---------------------------------

The comparison has been made between: i) 4 normal tissues brain removed with *post mortem* autopsy by normal donors (2 males and 2 females); ii) 27 non-tumor peripheral tissues brain removed during surgical resection on patients with GBM and 27 tumor tissues WHO grade IV GBM, specifically, by 14 male patients (58.3±10.0 years) and 13 female patients (58.3±12.6 years) ([Table 1](#T1){ref-type="table"}).

Table 1Expression PARP-1 protein in WHO glioblastoma multiforme grade IV astrocytoma.SexAge (years)Brain localizationHistological diagnosisPositive cell nuclei (%)Case 1Male41Right parietal lobeGlioblastoma IV WHO95Case 2Male61Right temporal lobeGlioblastoma IV WHO85Case 3Male51Left temporal lobeGlioblastoma IV WHO90Case 4Male67Right temporal lobeGlioblastoma IV WHO90Case 5Male66Right frontal lobeGlioblastoma IV WHO80Case 6Male68Left parietal lobeGlioblastoma IV WHO85Case 7Male60Left frontal lobeGlioblastoma IV WHO90Case 8Male68Right frontal lobeGlioblastoma IV WHO85Case 9Male66Right frontal lobeGlioblastoma IV WHO90Case 10Male53Right parietal lobeGlioblastoma IV WHO95Case 11Male51Left temporal lobeGlioblastoma IV WHO80Case 12Male60Left frontal lobeGlioblastoma IV WHO85Case 13Male38Left occipital lobeGlioblastoma IV WHO85Case 14Male66Left occipital lobeGlioblastoma IV WHO80Case 15Female50Left frontal lobeGlioblastoma IV WHO95Case 16Female69Left frontal lobeGlioblastoma IV WHO90Case 17Female66Left frontal lobeGlioblastoma IV WHO85Case 18Female43Right temporal lobeGlioblastoma IV WHO90Case 19Female62Right temporal lobeGlioblastoma IV WHO80Case 20Female60Right frontal lobeGlioblastoma IV WHO90Case 21Female67Left frontal lobeGlioblastoma IV WHO95Case 22Female28Right temporal lobeGlioblastoma IV WHO80Case 23Female50Brain ventricleGlioblastoma IV WHO85Case 24Female75Right frontal lobeGlioblastoma IV WHO90Case 25Female62Left frontal lobeGlioblastoma IV WHO80Case 26Female60Left frontal lobeGlioblastoma IV WHO90Case 27Female66Left frontal lobeGlioblastoma I VWHO85Autopsy 1Male66Right frontal lobeNormalNot applicableAutopsy 2Male54Brain ventricleNormalNot applicableAutopsy 3Female41Right parietal lobeNormalNot applicableAutopsy 4Female70Right temporal lobeNormalNot applicable

Diagnoses of GBM were made on histological sections stained with hematoxylin-eosin and the sections were evaluated by at least two operators. The protocol was approved by the internal Institutional Review Board and an informed written consent was obtained from each patient with GBM or, if deceased, by his/her relatives.

Immunohistochemical staining
----------------------------

Brain sections (4 µm thick) were obtained from all normal donors and GMB patients. Brain sections from GBM patients included both GBM and normal tissue ([Table 1](#T1){ref-type="table"}). All sections were formalin-fixed and paraffin-embedded following standard methods.

PARP-(F-2), a mouse monoclonal antibody raised against PARP-1 protein, was used for immunohistochemistry (Santa Cruz Biotechnology, Inc., Heidelberg, Germany) PARP-1 (F-2): sc-8007). As indicated by the manufacturer instructions, this antibody, at the dilution of 1:300, has been shown to reliably recognize PARP-1 proteins in glioblastomas and normal brain by immunohistochemistry. Slides were deparaffinized, rehydrated, subjected to three 5-min cycles in a microwave at 360 W in citrate buffer, preincubated in 3% H~2~O~2~ in citrate buffer, and thoroughly washed in 50 mm Tris-Cl (pH 7.4), 150 mm NaCl Tris buffered saline (TBS) containing 0.05% Tween 20 (washing buffer). Slides were then preincubated with 3% bovine serum albumin (BSA) in TBS for 30 min, incubated with 1:300 dilution of anti-PARP-1 antibody in TBS containing 1% BSA, thoroughly washed in washing buffer before detection with the LSAB 2 kit (anti mouse, biotinylated and peroxidase-labeled streptavidin) and 3,3-diaminobenzidine-4HCl (DAB; Dako, Carpinteria, CA, USA) from Dako, following the instructions contained in the kit. After detection, the sections were counterstained with haematoxylin, dehydrated and mounted in xylen-based DPX mountant (BDH, Pool, UK).^[@R12]^

Microscopic evaluation
----------------------

Slides were observed and cells visually scored at 20× and 40×. To evaluate the percentage of positive tumor cells, microscopic fields were chosen such that non-tumor cells were also included. The fraction of PARP-1 positive cells was evaluated independently in a blinded fashion by two co-authors. No significant difference was observed between the two observers.

Statistical analysis
--------------------

Results are expressed as mean±SEM. Data were analyzed by chi-square test and statistical analysis was performed with Graph Pad Prism 5 software (Graph Pad Software, Inc. La Jolla, CA, USA). The statistical significance was accepted for the p value lower than 0.05.

Results {#S3}
=======

Normal tissues (4 autopsies and 27 non-tumoral tissue of the same subjects with brain GBM) did not show any nuclear or cytoplasmic signal for the protein PARP-1 ([Table 1](#T1){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}A). The expression of PARP-1 was also evaluated in 27 samples of GBM, PARP-1 positive nuclear signal was present in all 27 samples with the mean of nuclei involved of 87.03±5.04% (P\<0.005). No cytoplasmic staining was observed in the samples ([Table 1](#T1){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}B). The signal was present on the nuclear membrane and nuclear chromatin.

Figure 1Immunohistochemistry of brain and glioblastoma multiforme IV WHO. A) Normal Brain, autopsy 3 (right parietal lobe); B) Glioblastoma multiforme IV WHO, case 1 (right parietal lobe); A and B hematoxylin counterstain; scale bar: 80 mm).

Discussion {#S4}
==========

This study showed that PARP-1 protein is detectable in GBM cells, but is undetectable in normal brain tissue. The protein seems to be exclusively localized in the nucleus. This observation suggests that *PARP-1* may play a role in this tumor and that the presence of the protein may be used as a cell marker. Indeed, previous studies^[@R13],[@R14]^ found the expression of *PARP-1* in brain whit GBM, in normal brain and in nucleus and cytoplasm of human neurons, also Wharton *et al.* 2000^[@R15]^ have observed expression of *PARP-1* in multicellular tumour spheroids, derived from human glioma cell lines.

*PARP-1* gene plays a significant role in cell death both in cell necrosis and in apoptosis. Massive DNA damage that typically results from necrotic stimuli elicits a major increase of *PARP-1* activity, which rapidly depletes the intracellular concentration of nicotine adenine dinucleotide (NAD^+^) and ATP. Increased consumption of ATP, in the effort to re-synthesize NAD^+^, leads to energy crisis culminating in cell death.^[@R16]^ This may in part justify the presence of PARP-1 protein in GBMs and in other tumors, such as ovarian, endometrial, lung, breast, skin cancers, and non-Hodgkin\'s lymphoma,^[@R11]^ as well as in a patients with Parkinson disease and multiple head and neck squamous cell in whom we recently reported an increased PARP-1 mRNA expression.^[@R17]^

The understanding of the mechanism that activates the expression of *PARP-1* gene requires significant further work to characterize its inter-domain interactions and its DNA-dependence, both at a structural and a functional level.^[@R18]^ Nonetheless, Eustermann and colleagues provided valuable insights into recognition of chromosomal DNA single-strand breaks, the crucial first step of the activation process, by *PARP-1* DNA binding domain.^[@R18]^ In fact, PARP-1 is a highly abundant chromatin-associated enzyme present in all higher eukaryotic cell nuclei, where it plays key roles in maintenance of genomic integrity, chromatin remodeling, and transcriptional control. *PARP-1* gene product binds to DNA single- and double-strand breaks through an N-terminal region containing two zinc fingers, F1 and F2. The C-terminal catalytic domain of the PARP-1 protein is activated via an unknown mechanism, causing formation and addition of the poly (adenosine diphospho-ribose) complex to acceptor proteins including PARP-1 itself.^[@R19]^

Several reports from various laboratories indicate that inhibition or absence of *PARP-1* provides remarkable protection in disease models, such as septic shock, diabetes, stroke, myocardial infarction, and ischemia, which are characterized predominantly by programmed-necrotic cell death.^[@R20]^ In addition, *PARP-1* activation has been causally connected to photoreceptor cell death;^[@R21]^ this observation has more recently been confirmed by other authors,^[@R22]^ who showed a causal involvement of PARP-1 in retinal degeneration, a neurodegenerative diseases affecting photoreceptors and causing blindness in humans. Some authors, besides, observed that poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity against intracranial melanoma, glioma, lymphoma, hematological neoplasias;^[@R23]--[@R25]^ these data suggest the potential role that could have PARP-1 inhibitors in the therapy against glioblastoma.

Activation of *PARP-1* in response to DNA damage is an important mechanism to keep homeostasis or to trigger apoptosis. The expression and function of PARP-1 has been studied in primary human lung cell cultures from normal human bronchial epithelial cells (NHBEC) and peripheral lung cells (PLC) from lung cancer patients grown as explant cultures over a period of 12 weeks. PARP-1 protein was expressed in all the cell culture derived from bronchial epithelium explants.^[@R26]^ Overall, recent data on *PARP-1* agree on the meaning of this gene expression in tumors. Accordingly, the results of this study indicate that *PARP-1* gene may play a role in GBMs.

In conclusion, PARP-1 protein (with this antibody) is detectable in the nuclei of all GBM cells, but is undetectable in normal cells. Given the role of PARP-1 protein in cell death (both necrosis and apoptosis) and in DNA repair mechanisms, it may be hypothesized that the presence of PARP-1 protein in the nucleus of the GBM is an attempt to trigger apoptosis in this type of tumor as well as in many other cancers.^[@R11],[@R17]^ In the context of the tumor biology, this may be envisioned as a defense mechanism regardless of the outcome on the prognosis of patients with GBM. Finally, the evidence that PARP-1 positive staining is exclusively present within the nucleus adds further evidence for the above-mentioned role played by this protein.
